Orlistat
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Orlistat: From Obesity to Hypervitaminosis
One-Sentence Summary
Orlistat is a lipase inhibitor originally used to treat obesity, including monogenic obesity. The TxGNN model predicts it may be effective for hypervitaminosis, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Obesity disorder; monogenic obesity |
| Predicted New Indication | Hypervitaminosis |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid authorizations) |
| Number of NDAs | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, orlistat is a gastric and pancreatic lipase inhibitor that reduces dietary fat absorption by roughly 30%.
Fat-soluble vitamins (A, D, E, K) are absorbed together with dietary fat, so reduced fat absorption could in theory lower their uptake. This gives a plausible but purely theoretical rationale for fat-soluble vitamin excess.
There are important limits to this reasoning:
- Lowering vitamin absorption is generally regarded as an adverse effect of orlistat (risk of vitamin deficiency), not a therapeutic benefit.
- It would not apply to excess of water-soluble vitamins.
- It would not address excess from non-dietary sources, such as injected or supplemental vitamins.
- The very high TxGNN score (99.42%) is a computational prediction only and is not backed by clinical or literature evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA020766 | ORLISTAT (H2-Pharma LLC) | Capsule | Not listed; status: cancelled |
| NDA021887 | ALLI (Aphena Pharma Solutions - Tennessee, LLC) | Capsule | Not listed; status: cancelled |
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from drug-disease relationships in the TxGNN knowledge graph, not from label text): liver failure, primary hyperoxaluria, anorexia nervosa, bulimia nervosa, vitamin deficiency disorder, cholestasis, benign recurrent intrahepatic cholestasis, familial intrahepatic cholestasis, drug-induced liver injury.
- Vitamin deficiency disorder is especially relevant here, because the proposed use depends on lowering vitamin absorption.
- Drug Interactions: 100 interactions were found in total. The first 20 returned are mostly Moderate, with a few Minor. Examples:
- Moderate: abacavir, lamivudine, emtricitabine, atazanavir, acarbose, albiglutide, alogliptin, canagliflozin, metformin, chlorpropamide, amiodarone, cannabidiol, asparaginase products, brentuximab vedotin, calaspargase pegol, clofarabine
- Minor: cholecalciferol, calcifediol, calcitriol
For package-insert warnings, please refer to the official label.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials or literature (Evidence Level L5). The proposed mechanism, reduced fat-soluble vitamin absorption, is a known adverse effect of orlistat rather than an established benefit. Both US authorizations are cancelled.
To proceed, the following is needed:
- Clinical or literature evidence for orlistat in fat-soluble vitamin excess
- Detailed mechanism of action data
- FDA package insert warnings and contraindications
- Assessment of whether lowering vitamin absorption can be done safely, given the contraindication for vitamin deficiency disorder
- Clarification of the regulatory pathway, since no US authorizations are currently valid
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.